KR101455447B1 - Ｍｕｃ１＊ 항체 - Google Patents

Ｍｕｃ１＊ 항체 Download PDF

Info

Publication number
KR101455447B1
KR101455447B1 KR1020117010349A KR20117010349A KR101455447B1 KR 101455447 B1 KR101455447 B1 KR 101455447B1 KR 1020117010349 A KR1020117010349 A KR 1020117010349A KR 20117010349 A KR20117010349 A KR 20117010349A KR 101455447 B1 KR101455447 B1 KR 101455447B1
Authority
KR
South Korea
Prior art keywords
seq
ser
sequence
thr
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020117010349A
Other languages
English (en)
Korean (ko)
Other versions
KR20110067153A (ko
Inventor
산지브 마한타
신디아 밤다드
Original Assignee
미네르바 바이오테크놀로지 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 미네르바 바이오테크놀로지 코포레이션 filed Critical 미네르바 바이오테크놀로지 코포레이션
Publication of KR20110067153A publication Critical patent/KR20110067153A/ko
Application granted granted Critical
Publication of KR101455447B1 publication Critical patent/KR101455447B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001116—Receptors for cytokines
    • A61K39/001117—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR] or CD30
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020117010349A 2008-10-06 2009-10-06 Ｍｕｃ１＊ 항체 Active KR101455447B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10320408P 2008-10-06 2008-10-06
US61/103,204 2008-10-06
PCT/US2009/059754 WO2010042562A2 (en) 2008-10-06 2009-10-06 Muc1* antibodies

Publications (2)

Publication Number Publication Date
KR20110067153A KR20110067153A (ko) 2011-06-21
KR101455447B1 true KR101455447B1 (ko) 2014-10-27

Family

ID=42101177

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117010349A Active KR101455447B1 (ko) 2008-10-06 2009-10-06 Ｍｕｃ１＊ 항체

Country Status (8)

Country Link
US (4) US20170204191A1 (enExample)
EP (3) EP3130607B1 (enExample)
JP (3) JP2012504961A (enExample)
KR (1) KR101455447B1 (enExample)
CN (1) CN102239182B (enExample)
CR (1) CR20110238A (enExample)
IL (1) IL212175B (enExample)
WO (1) WO2010042562A2 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012504961A (ja) 2008-10-06 2012-03-01 ミネルバ バイオテクノロジーズ コーポレーション Ｍｕｃ１＊抗体
KR20160017117A (ko) * 2008-10-09 2016-02-15 미네르바 바이오테크놀로지 코포레이션 세포내에서 다능성을 유도하기 위한 방법
US8518405B2 (en) * 2009-10-08 2013-08-27 The University Of North Carolina At Charlotte Tumor specific antibodies and uses therefor
EP3228629A1 (en) * 2010-06-16 2017-10-11 Minerva Biotechnologies Corporation Reprogramming cancer cells
EP2407487A1 (en) 2010-07-14 2012-01-18 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Multispecific modular antibody
US9845362B2 (en) 2010-10-08 2017-12-19 The University Of North Carolina At Charlotte Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same
EP4086338A1 (en) * 2011-03-17 2022-11-09 Minerva Biotechnologies Corporation Method for making pluripotent stem cells
CN102716472A (zh) * 2011-03-31 2012-10-10 李光辉 一种肿瘤疫苗及其合成方法
WO2014012115A2 (en) * 2012-07-13 2014-01-16 Minerva Biotechnologies Corporation Method for inducing cells to less mature state
AU2013302620B2 (en) * 2012-08-14 2018-08-02 Minerva Biotechnologies Corporation Stem cell enhancing therapeutics
WO2014052693A2 (en) * 2012-09-29 2014-04-03 The Trustees Of The University Of Pennsylvania Veterinary composition and methods for non-surgical neutering and castration
CN103848890B (zh) * 2012-11-30 2015-09-09 北京市结核病胸部肿瘤研究所 Muc1自身抗体识别的抗原多肽
US9988442B2 (en) 2013-01-23 2018-06-05 Syddansk Universitet MFAP4 binding antibodies blocking the interaction between MFAP4 and integrin receptors
CN106132992B (zh) * 2014-01-29 2020-08-07 达娜-法勃肿瘤研究所公司 针对muc1-c/胞外结构域(muc1-c/ecd)的抗体
CN103880956B (zh) * 2014-03-10 2015-12-30 中国人民解放军第四军医大学 抗muc1单克隆抗体及其轻链和重链可变区
EP4050103A1 (en) 2014-04-07 2022-08-31 Minerva Biotechnologies Corporation Anti-nme antibody
US11554181B2 (en) 2014-09-05 2023-01-17 The University Of North Carolina At Charlotte Tumor specific antibody conjugates and uses therefor
MX378108B (es) * 2014-09-16 2025-03-10 Servier Lab Anticuerpos anti-met y composiciones.
KR102390359B1 (ko) * 2014-09-29 2022-04-22 삼성전자주식회사 폴리펩타이드, 이를 포함하는 항 VEGF 항체 및 항 c-Met/항 VEGF 이중 특이 항체
CN106999587B (zh) 2014-10-02 2023-09-29 希望之城公司 多价中间表位，中间表位结合抗体及其用途
EP3204414B1 (en) 2014-10-07 2024-12-04 Ann and Robert H. Lurie Children's Hospital of Chicago Novel anti-nodal antibodies and methods of using same
EP3256494A4 (en) 2015-02-10 2018-12-05 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies
CA3007646A1 (en) * 2015-12-09 2017-06-15 Bioatla, Llc Humanized anti-cd73 antibodies
EP3450460B1 (en) * 2016-04-29 2023-07-12 Benhealth Biopharmaceutic (Shenzhen) Co. Ltd. Multi-specific binding conjugate, related pharmaceutical compositions and use
US20190343953A1 (en) * 2017-01-27 2019-11-14 Glycotope Gmbh Anti-cancer treatments with an anti-muc1 antibody and an erbb inhibitor
JP7160833B2 (ja) * 2017-04-13 2022-10-25 サイロパ ビー．ブイ． 抗ｓｉｒｐアルファ抗体
US12605469B2 (en) 2017-10-02 2026-04-21 The University Of North Carolina At Charlotte Tumor specific antibody conjugates and uses therefor
CN109971713B (zh) * 2017-12-28 2023-06-20 上海细胞治疗研究院 稳定表达PD-1抗体的Muc1特异性CAR-T细胞及其用途
CN112040985A (zh) * 2018-02-07 2020-12-04 瑞泽恩制药公司 用于递送治疗性蛋白质的方法和组合物
US20200405832A1 (en) * 2018-03-09 2020-12-31 Minerva Biotechnologies Corporation Method for anti-muc1* car t cell stimulation
WO2020146902A2 (en) * 2019-01-11 2020-07-16 Minerva Biotechnologies Corporation Anti-variable muc1* antibodies and uses thereof
EP3920693A4 (en) 2019-02-04 2022-10-05 Minerva Biotechnologies Corporation ANTI-NME ANTIBODIES AND METHODS OF TREATMENT OF CANCER OR CANCER METASTASIS
WO2021081232A1 (en) 2019-10-23 2021-04-29 Cue Biopharma, Inc. Modified cytotoxic t cells and methods of use thereof
JP2023530039A (ja) 2020-06-08 2023-07-12 ミネルバ バイオテクノロジーズ コーポレーション 抗ｎｍｅ抗体および癌または癌転移の治療方法
CA3183682A1 (en) 2020-06-26 2021-12-30 Minerva Biotechnologies Corporation Anti-nme antibody and method of treating cancer or cancer metastasis
EP4182354A4 (en) * 2020-07-16 2024-12-25 Dana-Farber Cancer Institute, Inc. ANTIBODIES AGAINST EXTRACELLULAR DOMAIN/MUC1-C (MUC1-C/ECD)
CN116322770A (zh) * 2020-07-31 2023-06-23 R·P·舍勒科技有限责任公司 对粘蛋白-1特异的抗体及其使用方法
KR102811084B1 (ko) 2020-12-24 2025-05-23 주식회사 엘지화학 뮤신 1에 특이적인 폴리펩티드 및 이의 이용
WO2022156799A1 (zh) * 2021-01-25 2022-07-28 成都康弘生物科技有限公司 一种抗体及其用途
CA3248038A1 (en) 2022-04-12 2023-10-19 Minerva Biotechnologies Corporation ANTI-MUC1* VARIABLE ANTIBODIES AND RELATED USES
WO2024146536A1 (en) * 2023-01-04 2024-07-11 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-muc1 antibodies and uses thereof
US20240261406A1 (en) 2023-02-02 2024-08-08 Minerva Biotechnologies Corporation Chimeric antigen receptor compositions and methods for treating muc1* diseases
EP4587063A1 (en) 2023-10-11 2025-07-23 Minerva Biotechnologies Corporation Anti-muc1* antibody drug complexes and uses thereof
WO2026064255A1 (en) * 2024-09-17 2026-03-26 The Trustees Of Columbia University In The City Of New York Chimeric antigen receptor (car) tregs against pan class i swine leukocyte antigen and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030235868A1 (en) * 2002-04-22 2003-12-25 Dyax Corporation Antibodies specific for mucin polypeptide
US20060222637A1 (en) * 2005-03-30 2006-10-05 Bamdad Cynthia C Proliferation of muc1 expressing cells

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
GB9412230D0 (en) 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US5874540A (en) * 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
US20020136725A1 (en) * 1996-01-17 2002-09-26 Smithkline Beecham Corporation Antithrombotic agents
TWI242563B (en) 1998-04-30 2005-11-01 Tanox Inc Monoclonal agonist antibodies which specifically bind to or interact with human G-CSF receptor
CA2348781A1 (en) 1998-11-12 2000-05-25 Novolytics Inc. Compositions and methods for producing vascular occlusion
US20020064528A1 (en) 2000-01-28 2002-05-30 Zhenping Zhu Antibodies specific to KDR and uses thereof
US20020052311A1 (en) 1999-09-03 2002-05-02 Beka Solomon Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders
WO2001075110A2 (en) * 2000-03-30 2001-10-11 Dyax Corp. Mucin-1 specific binding members and methods of use thereof
DE60130891T2 (de) 2000-06-29 2008-07-17 Anthera Pharmaceuticals Inc., San Mateo Heilmittel für krebs
WO2002022685A2 (en) 2000-09-11 2002-03-21 Kufe Donald W Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom
US7700715B2 (en) * 2000-11-27 2010-04-20 Minerva Biotechnologies Corporation Diagnostic tumor markers, drug screening for tumorigenesis inhibition, and compositions and methods for treatment of cancer
WO2002078598A2 (en) 2001-03-29 2002-10-10 Ramot University Authority For Applied Research & Industrial Development Ltd. Peptides and antibodies to muc 1 proteins
US7630836B2 (en) 2001-05-30 2009-12-08 The Kitasato Institute Polynucleotides
EP1425016B1 (en) 2001-09-05 2010-06-02 Minerva Biotechnologies Corporation Compositions and methods of treatment of cancer
CA2478047C (en) * 2002-03-01 2014-01-21 Immunomedics, Inc. Rs7 antibodies
ES2524767T3 (es) * 2002-06-14 2014-12-12 Immunomedics, Inc. Anticuerpo monoclonal humanizado HPAM4
JP2007531505A (ja) * 2002-11-27 2007-11-08 ミネルバ バイオオテクノロジーズ コーポレーション 癌（ｍｕｃ１）の診断および治療のための技術および組成物
US7101978B2 (en) * 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
US20060173171A1 (en) 2003-08-26 2006-08-03 Bamdad Cynthia C Techniques and compositions for diagnosis and treatment of cancer (muci)
EP2168986A3 (en) * 2004-02-19 2010-07-28 Genentech, Inc. CDR-repaired antibodies
CN101035810B (zh) 2004-10-04 2011-04-06 健泰科生物技术公司 肝细胞生长因子激活剂的调控物
US20090075926A1 (en) 2006-12-06 2009-03-19 Bamdad Cynthia C Method for identifying and manipulating cells
WO2008073817A2 (en) * 2006-12-08 2008-06-19 Dana-Farber Cancer Institute, Inc. Muc1 and galectin-3
JP2012504961A (ja) 2008-10-06 2012-03-01 ミネルバ バイオテクノロジーズ コーポレーション Ｍｕｃ１＊抗体
AU2013302620B2 (en) * 2012-08-14 2018-08-02 Minerva Biotechnologies Corporation Stem cell enhancing therapeutics
EP3256494A4 (en) * 2015-02-10 2018-12-05 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030235868A1 (en) * 2002-04-22 2003-12-25 Dyax Corporation Antibodies specific for mucin polypeptide
US20060222637A1 (en) * 2005-03-30 2006-10-05 Bamdad Cynthia C Proliferation of muc1 expressing cells

Also Published As

Publication number Publication date
EP3130607B1 (en) 2024-04-17
US10421819B2 (en) 2019-09-24
JP2017176174A (ja) 2017-10-05
US20180222998A1 (en) 2018-08-09
US20200239594A1 (en) 2020-07-30
JP6230983B2 (ja) 2017-11-15
EP4083072B1 (en) 2026-02-18
EP4083072A1 (en) 2022-11-02
EP3130607A2 (en) 2017-02-15
JP2012504961A (ja) 2012-03-01
US20170204191A1 (en) 2017-07-20
IL212175A0 (en) 2011-06-30
CN102239182A (zh) 2011-11-09
WO2010042562A3 (en) 2010-09-30
CN102239182B (zh) 2014-07-09
KR20110067153A (ko) 2011-06-21
JP2015071614A (ja) 2015-04-16
IL212175B (en) 2019-08-29
US20230295340A1 (en) 2023-09-21
EP2337801A2 (en) 2011-06-29
EP2337801A4 (en) 2012-07-25
JP6392923B2 (ja) 2018-09-19
US11560435B2 (en) 2023-01-24
CR20110238A (es) 2012-05-29
WO2010042562A2 (en) 2010-04-15
EP3130607A3 (en) 2017-06-28

Similar Documents

Publication Publication Date Title
US20230295340A1 (en) Muc1* antibodies
KR102924006B1 (ko) 항-pd-l1/항-4-1bb 이중특이적 항체 및 이의 용도
KR102365972B1 (ko) 항-pd-1 항체 및 이의 용도
CN112566662A (zh) 针对cd47的阻断抗体及其使用方法
JP2026001061A (ja) 抗ｄｌｌ３キメラ抗原受容体及びその使用
CN112574310B (zh) 抗SIRPα抗体及其用途
WO2017071625A1 (zh) 一种抗pd-1单克隆抗体、其药物组合物及其用途
KR20140018837A (ko) 노텀 단백질 조절 인자 및 사용 방법
WO2021097800A1 (en) Anti-pd-l1/anti-b7-h3 multispecific antibodies and uses thereof
CN109776677B (zh) 一种人源化抗il-13抗体及其制备方法和应用
CN115386006A (zh) 抗gprc5d抗体、其制备方法与用途
US20240018255A1 (en) ANTI-SIRPalpha ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, AND USE THEREOF
US20240101663A1 (en) Method for inhibiting tumour cell growth based on ccdc112
CN117164719A (zh) 靶向SIRPα和PD-L1的双特异性抗体或其抗原结合片段及应用
AU2022340589A1 (en) Bi-functional fusion protein and uses thereof
HK40082756A (en) Muc1* antibodies
CN114773467B (zh) 抗SIRPα抗体或其抗原结合片段及应用
KR101599370B1 (ko) Jagged 1에 대한 인간 단일클론항체 J1J22
HK40128404A (en) Trop2 antibodies
CN119698435A (zh) 抗ilt4抗体及其医药用途
HK40016537B (en) Anti-pd-1 antibodies and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20110504

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20111028

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130527

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20140321

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20130527

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20140321

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20131127

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20111028

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20140721

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20140623

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20140321

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20131127

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20111028

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20141021

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20141021

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20181001

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20181001

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20190926

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20190926

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20211202

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20231011

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20241008

Start annual number: 11

End annual number: 11